Everything below concerns peptide research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
== Degradation == Once secreted, GLP-1 is extremely susceptible to the catalytic activity of the proteolytic enzyme dipeptidyl peptidase-4 (DPP-4). Specifically, DPP-4 cleaves the peptide bond between Ala8-Glu9 resulting in the abundant GLP-1 (9–36) amide constituting 60–80% of total GLP-1 in circulation. DPP-4 is widely expressed in multiple tissues and cell types and exists in both a membrane-anchored and soluble circulating form. Notably, DPP-4 is expressed on the surface of endothelial cells, including those located directly adjacent to GLP-1 secretion sites. Consequently, less than 25% of secreted GLP-1 is estimated to leave the gut intact. Additionally, presumably due to the high concentration of DPP-4 found on hepatocytes, 40–50% of the remaining active GLP-1 is degraded across the liver. Thus, due to the activity of DPP-4 only 10–15% of secreted GLP-1 reaches circulation intact. Neutral endopeptidase 24.11 (NEP 24.11) is a membrane-bound zinc metallopeptidase widely expressed in several tissues, but found in particularly high concentrations in the kidneys, which is also identified accountable for the rapid degradation of GLP-1. It primarily cleaves peptides at the N-terminal side of aromatic or hydrophobic amino acids and is estimated to contribute by up to 50% to GLP-1 degradation. However, the activity only becomes apparent once the degradation of DPP-4 has been prevented, as the majority of GLP-1 reaching the kidneys has already been processed by DPP-4. Similarly, renal clearance appears more significant for the elimination of already inactivated GLP-1.
Other tyrannosaur fossils found in the same formations as T. rex were originally classified as separate taxa, including Aublysodon and Albertosaurus megagracilis, the latter being named Dinotyrannus megagracilis in 1995. These fossils are now universally considered to belong to juvenile T. rex. A small but nearly complete skull from Montana, 57.2 centimeters (1.88 ft) long, is an exception. This skull, CMNH 7541, was originally classified as a species of Gorgosaurus (G. lancensis) by Charles W. Gilmore in 1946. In 1988, the specimen was re-described by Robert T. Bakker, Michael Williams, then the curator of paleontology at the Cleveland Museum of Natural History, and Phil Currie, where the original specimen was housed and is now on display. Their initial research indicated that the skull bones were fused, and that it therefore represented an adult specimen. In light of this, Bakker and colleagues assigned the skull to a new genus named Nanotyrannus (meaning "dwarf tyrant", for its apparently small adult size). However, in 1999, a detailed analysis by Thomas Carr revealed the specimen to be a juvenile, leading Carr and many other paleontologists to consider it a juvenile T. rex individual.
2 CH3C(O)CO2H → (O=C)(HOC)(HC)C(CH3)(CO2H) + H2O The dehydration can be induced by distillation of pyruvic acid. Zymonic acid in turn forms a variety of derivatives in aqueous solution. Pyruvic acid is a precursor to several types of heterocycles. When treated with phenethylamine, it gives tetrahydroisoquinoline by a sequential condensation/acylation process (Bischler–Napieralski reaction). With ortho-phenylenediamine it condenses to give quinoxalines. Condensation with 4,5-diaminopyrimidine give hydroxypteridines.
Sources: en.wikipedia.org
Benoît Duteurtre published in 2001, Le Voyage en France (Travel in France), for which he received the Prix Médicis: the main character, a young American impassioned by France, lands at Le Havre which he describes in the first part of the novel. In 2008, Benoît Duteurtre publishes Les pieds dans l'eau (Feet in the water), a highly autobiographical book in which he describes his youth spent between Le Havre and Étretat. The city hosted writers such as Emile Danoën (1920–1999) who grew up in the district of Saint-François, Yoland Simon (born 1941), and Philippe Huet (born 1955). Canadian poet Octave Crémazie (1827–1879) died at Le Havre and was buried in Saint Marie Cemetery. The playwright Jacques-François Ancelot (1794–1854) was also a native of Le Havre. Two famous historians, Gabriel Monod (1844–1912) and André Siegfried (1875–1959) were from the city. Le Havre also appears in comic books: for example, in L'Oreille cassée (The Broken Ear) (1937), Tintin embarks on the vessel City of Lyon sailing to South America. The meeting between Tintin and General Alcazar in Les Sept Boules de cristal (The Seven Crystal Balls) (1948) is in Le Havre, according to notes by Hergé in the margins of Le Soir, the first publisher of this adventure. The first adventure of Ric Hochet (1963), the designer Tibet and André-Paul Duchâteau, Traquenard au Havre (Trap at Le Havre) shows the seaside and the port. Similarly, in 1967, for the album Rapt sur le France (Rapt on France), the hero passes by the ocean port.
A catch bond is a type of noncovalent bond whose dissociation lifetime increases with tensile force applied to the bond. Normally, bond lifetimes are expected to diminish with force. In the case of catch bonds, the lifetime of the bond actually increases up to a maximum before it decreases like in a normal bond. Catch bonds work in a way that is conceptually similar to that of a Chinese finger trap. While catch bonds are strengthened by an increase in force, the force increase is not necessary for the bond to work. Catch bonds were suspected for many years to play a role in the rolling of leukocytes, being strong enough to roll in presence of high forces caused by high shear stresses, while avoiding getting stuck in capillaries where the fluid flow, and therefore shear stress, is low. The existence of catch bonds was debated for many years until strong evidence of their existence was found in bacteria. Definite proof of their existence came shortly thereafter in leukocytes.
High-resolution Nuclear Magnetic Resonance. McGraw-Hill Book Company. John D. Roberts (1959). Nuclear Magnetic Resonance: applications to organic chemistry. McGraw-Hill Book Company. ISBN 978-1-258-81166-2. {{cite book}}: ISBN / Date incompatibility (help) Charles P. Slichter (1963). Principles of magnetic resonance: with examples from solid state physics. Harper & Row. ISBN 978-3-540-08476-1. {{cite book}}: ISBN / Date incompatibility (help) J.M. Tyszka; S.E. Fraser; R.E. Jacobs (2005). "Magnetic resonance microscopy: recent advances and applications". Current Opinion in Biotechnology. 16 (1): 93–99. doi:10.1016/j.copbio.2004.11.004. PMID 15722021. Kurt Wüthrich (1986). NMR of Proteins and Nucleic Acids. New York (NY), US: Wiley-Interscience. ISBN 978-0-471-11917-3.
After returning from the DL, Helton played only 6 games before announcing that he would have season-ending hip surgery in order to prepare for the 2013 season. Helton was healthier in 2013, playing in 124 games, while hitting 15 home runs with 61 RBIs. On September 14, 2013, Helton announced that he would be retiring at the conclusion of the 2013 season. On September 25, before his last game at Coors Field, Helton was honored by the Rockies in a pre-game ceremony. In the game, Helton hit a home run and drove in three runs versus the Boston Red Sox. On August 17, 2014, the Rockies retired Helton's number 17 before a game at Coors Field. He was the first Rockies player to have his number retired in the franchise's history.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.